Clinical trialNCT04559230RecruitingPhase 2Interventional

Sacituzumab Govitecan in Recurrent Glioblastoma

SponsorThe University of Texas Health Science Center at San AntonioEnrollment32Recurrent Glioblastoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on treatment with Sacituzumab Govitecan (SG) versus lomustine only which has been used in the past.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

William Kelly, MD
Mays Cancer Center, UT Health San Antonio
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
Mina Lobbous, MD
Recruiting
Texas Oncology Austin
Austin, Texas, United States
Brian Valliant, MD
Recruiting
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center
San Antonio, Texas, United States
William Kelly, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Sacituzumab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Jan 2022
Primary completion: 28 Feb 2027
Completion: 29 Feb 2028
Last update posted: 30 Mar 2026
Registered enrollment: 32
Registry id: NCT04559230

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.